Immupharma PLC AIM Rule 17 Notice (4650O)
August 18 2017 - 12:09PM
UK Regulatory
TIDMIMM
RNS Number : 4650O
Immupharma PLC
18 August 2017
18 August 2017
ImmuPharma Plc
AIM Rule 17 Notice
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces
pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"),
the following director's disclosure under Schedule Two, Paragraph
(g) of the AIM Rules:
Tim McCarthy, the Company's Non-executive Chairman, previously
held roles on the boards of Alizyme Plc and its subsidiary Alizyme
Therapeutics Ltd, both of which entered into a Creditors Voluntary
Winding-up in December 2009, within 12 months of his
resignation.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Ends
For further information please contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited
(NOMAD & Broker)
Patrick Claridge, David Hignell,
Jamie Spotswood, Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKFDKABKDOFD
(END) Dow Jones Newswires
August 18, 2017 12:09 ET (16:09 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024